Parabilis Medicines, Inc. (PBLS) Stock Analysis & Investment Frameworks
Parabilis Medicines, Inc. (PBLS) stock analysis on Invetso. Review Parabilis Medicines, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Parabilis Medicines, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Parabilis Medicines, Inc. Key Financial Metrics
- Market Cap: $3.48B
- Revenue: $N/A
- ROE: -15.14%
- ROIC: -8.73%
- Dividend Yield: N/A
About Parabilis Medicines, Inc.
Parabilis Medicines, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.